Navigation Links
A new step towards an AIDS vaccine

Progressive disease after HIV infection is inversely correlated with the presence of plasmacytoid dendritic cells (pDCs), a subset of the dendritic cell family and the major producers of type 1 interferon in the body. High numbers of pDCs is related to successful control of HIV. In a paper appearing online on October 13 in advance of print publication of the November issue of the Journal of Clinical Investigation, Nina Bhardwaj and colleagues from New York University report the mechanisms by which HIV-1 activates human pDCs.

The authors show that pDC activation by HIV-1 requires at least two interactions between the cell and virus. Initially, envelope-CD4 interactions mediate the endocytosis of HIV-1. Next, viral nucleic acids, particularly RNA, stimulate pDCs through Toll-like receptors.

A decrease of blood pDC frequency is typically observed in chronic infections due to HIV-1 and correlates with high viral load, reduced CD4 counts and susceptibility to opportunistic infections, and is only partially reverted by anti-retroviral therapy. By identifying the active component of HIV-1 which stimulates pDC function, and consequently other antigen presenting cell function, the authors have recognized an important pathway whereby DC function can be targeted in the design of efficient vaccines or immunotherapies for HIV.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Virologists make major step towards understanding the process of HIV infection
2. Cats indifference towards sugar explained
3. New GM mosquito sexing technique is step towards malaria control, report scientists
4. Novel method reveals how menthol discovery could point towards new or improved pain therapies
5. Scientists make first step towards holy grail of crystallography
6. Salk researchers make fast strides towards understanding how our body controls walking
7. Research advances quest for HIV-1 vaccine
8. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
9. NIAID begins clinical trial of West Nile virus vaccine
10. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
11. Fragment of yellow fever virus may hold key to safer vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: new step towards AIDS vaccine

(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... Smith & Co., Inc.,acted as the exclusive advisor ... d/b/a NJOY, as announced by Charles Botchway, Group,Managing ... Company, Inc. The,transaction was led by Houlihan ... , "We appreciate the ...
... Bionics Inc., "Victhom" (TSX: VHB), today announced the ... www.victhom.com . The Website features a new structure ... divisions; Neurobionix, which is developing an implantable neurostimulation ... developing and manufacturing computerized prostheses for above-knee amputees. ...
... 9 /PRNewswire/ - Sirius Genomics, a developer of ... a collaborative agreement with the United Kingdom Critical ... the continued development of Sirius, pharmacogenomic diagnostic for ... Eli Lilly and Company under the trademark Xigris(R)). ...
Cached Biology Technology:Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2Victhom Announces Launch of Enhanced Company Website 2Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group 2
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
... qualitatively detect EGFR gene ... (FFPE) tissue sections, metaphase ... preparations, using Chromogenic In ... In Situ Hybridization (FISH) ...
Request Info...
Biology Products: